Your session is about to expire
← Back to Search
BTK Inhibitor
BGB-11417 for Mantle Cell Lymphoma
Phase 1 & 2
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a drug for relapsed or refractory mantle cell lymphoma to assess safety, tolerability, and efficacy.
Who is the study for?
This trial is for people with a confirmed diagnosis of mantle cell lymphoma (MCL) who have relapsed or are not responding to treatment. They must have measurable disease, previous treatments including CD20-based therapy and BTK inhibitors, and be in fairly good health based on ECOG status. People can't join if they've had certain recent transplants, active severe infections, cardiovascular issues, prior Bcl-2 inhibitor use like venetoclax, or other cancers within the last 3 years.
What is being tested?
The study tests BGB-11417 as a single agent for MCL that's come back or isn't getting better after treatment. It has two parts: first finding the safest dose and then checking how well it works at that dose against MCL.
What are the potential side effects?
While specific side effects of BGB-11417 aren't listed here, similar drugs often cause nausea, diarrhea, fatigue, low blood counts increasing infection risk; liver function changes; and potential allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Part 2: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
Secondary study objectives
Duration of Response (DOR) as assessed by investigator and IRC
Overall Response Rate (ORR) as assessed by investigator
Overall Survival (OS)
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Participants will receive sonrotoclax
Find a Location
Who is running the clinical trial?
BeiGeneLead Sponsor
195 Previous Clinical Trials
30,483 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My organs are working well.I have a serious heart condition.My diagnosis of mantle cell lymphoma is confirmed by tissue analysis.My condition has returned or didn't respond to treatment.I have had treatments for MCL including anti-CD20 therapy and a BTK inhibitor.I can provide tissue samples for my mantle cell lymphoma diagnosis.I am currently being treated for a serious infection.My lymphoma has spread to my brain or spinal cord.I have not had major surgery or a significant injury in the last 4 weeks.My cancer can be measured by tests.I can care for myself and am up and about more than 50% of my waking hours.I haven't had cancer in the last 3 years, except for certain non-aggressive types or skin cancer.I had a stem cell transplant or CAR T-cell therapy recently, or I'm currently on immunosuppressants for graft-vs-host disease.I have been treated with a BCL-2 inhibitor before.
Research Study Groups:
This trial has the following groups:- Group 1: Single Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger